Meningococcal surrogates of protection?serum bactericidal antibody activity

2005/01/15 by Ray Borrow, R BORROW, Paul Balmer +3 · 25 citations
Immunology and Microbiology · Medicine · #Antibiotics #Antibody #Bacteria #Bacterial Infections and Vaccines #Biology #Immune system #Immunization #Immunology #Medicine #Meningococcal disease #Meningococcal vaccine #Microbiology #Neisseria meningitidis #Neisseriaceae #Outbreak #Pneumonia and Respiratory Infections #Vaccination #Virology #Virology and Viral Diseases

paper · doi:10.1016/j.vaccine.2005.01.051

openalex publication_date 2005/01/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26

Citations

• Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era

Cited by

• Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. [europepmc]
• Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. [europepmc]
• Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. [europepmc]
• Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. [europepmc]
• Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. [europepmc]
• Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. [europepmc]
• Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. [europepmc]
• Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. [europepmc]
• Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. [europepmc]
• The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease. [europepmc]
• Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. [europepmc]
• Meningococcal serogroup B vaccines: Estimating breadth of coverage. [europepmc]
• Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment. [europepmc]
• Meningococcal Vaccines: Current Status and Emerging Strategies. [europepmc]
• Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. [europepmc]
• Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges. [europepmc]
• Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery. [europepmc]
• A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. [europepmc]
• Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines. [europepmc]
• IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. [europepmc]
• Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. [europepmc]
• Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications. [europepmc]
• Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. [europepmc]
• Peptide-Based Vaccines for Tuberculosis. [europepmc]
• Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia. [europepmc]